Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnose of COPD (criteria ATS/ERS 2004)~* Clinical stability more than 3 months~* Smokers or ex-smokers of more than \> 10 boxes/year than do not modify their smoking habit during the study.~* FEV1 (post-bronchodilator) \< 50%. FEV1/FVC ≤ 70~* Negative answer to bronchodilator(≤ 20% del FEV1 o ≤ 200 ml.after 400 mcg.de salbutamol inhaled)~* BMI \< 21 Kg/m2 ó BMI 21-25 Kg/m with loss weight of 5% of the habitual body weight in the last 3 months, without other reason that could explain it independently of the COPD.~Exclusion Criteria:~* Use of nasogastric catheter~* Concomitant treatment with steroid, anabolics or other progestagens.~* Loss of body weight related with other causes: hyperthyroidism, enteral malnutrition ( Crohn disease...), neoplasias,etc~* Treatment with Megestrol Acetate in the last 6 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Megestrol acetate: sachets of granulated 160 mg. Dose: 160 mg/b.i.d. Duration 8 weeks
- 2 (Type: PLACEBO_COMPARATOR): The placebo is the excipient of the experimental drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).